Camurus AB (LTS:0RD1) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RD1 Camurus AB LTS:0RD1
84 GF Score
Price kr615.00
GF Value kr712.73
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Camurus AB FFO per Share?

FFO per Share only applies to REITs.

LTS:0RD1
84GF Score
Camurus AB LTS:0RD1
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (LTS:0RD1) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of kr615.00 is trading 13.7% below its estimated GF Value™ of kr712.73. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for LTS:0RD1:

  • FFO per Share:
  • GF Value™: kr712.73 vs. price of kr615.00 (13.7% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
84GF Score

Get the complete analysis for LTS:0RD1

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr615.00
Price
kr712.73
GF Value